Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing oxidative stress and inflammation

Wang, Si-wei; Xu, Yi; Weng, Yuanyuan; Fan, Xueyu; Bai, Yang; Zheng, Xiaoyan; Lou, Li-Jun; Zhang, Feng

doi:10.1016/j.fct.2018.02.041

Cited by 96 publications

(52 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As Nrf2 plays a central role in regulating the endogenous antioxidant defense system, activation of Nrf2-ARE pathway is increasingly considered as a promising approach for treatment or prevention of neurodegenerative ailments [5,6]. Thus, extensive interests have been attracted to activate the Nrf2-ARE pathway for therapeutic purposes [7][8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Reversing ROS‐mediated neurotoxicity by chlorogenic acid involves its direct antioxidant activity and activation of Nrf2‐ARE signaling pathway

Yao

Peng

et al. 2019

BioFactors

View full text Add to dashboard Cite

Chlorogenic acid (CA), the ester of caffeic acid and quinic acid, is one of the most abundant polyphenols in coffee, and has multiple pharmacological functions. The present study is designed to explore the protection provided by CA against hydrogen peroxide (H2O2)‐induced oxidative damages in the rat pheochromocytoma cells, and the underlying mechanisms engaged in this process. CA displays robust free radical‐scavenging activity in vitro. More importantly, CA strikingly rescues the cells from the H2O2‐mediated oxidative insults. Mechanistic studies revealed that CA upregulates a panel of phase II cytoprotective species, such as heme oxygenase‐1, NAD(P)H: quinone oxidoreductase 1, glutathione, thioredoxin reductase 1, and thioredoxin 1. This neuroprotection is dependent on the activation of the transcription factor Nuclear factor erythroid 2‐related factor 2 (Nrf2), as knockdown of Nrf2 abolishes such effect. Our results demonstrate that CA provides dual neuroprotection via directly neutralizing free radicals and indirectly inducing expression of Nrf2‐driven cytoprotective enzymes, and suggest a potential therapeutic usage of CA as a neuroprotective agent. Coffee is one of the most popular drinks in the world, and our discovery may also contribute to understanding the beneficial effects of regular coffee consumption. © 2019 BioFactors, 45 (4):616–626, 2019

show abstract

Section: Introductionmentioning

confidence: 99%

Reversing ROS‐mediated neurotoxicity by chlorogenic acid involves its direct antioxidant activity and activation of Nrf2‐ARE signaling pathway

Yao

Peng

et al. 2019

BioFactors

View full text Add to dashboard Cite

show abstract

“…Astilbin, isolated from Rhizoma Smilacis Glabrae (a type of Chinese medicinal herb), has been reported to exert numerous bioactivities, including antioxidative and antibacterial activities . The compound also demonstrates functionality for the treatment of autoimmune diseases .…”

Section: Discussionmentioning

confidence: 99%

“…12,33 Astilbin, isolated from Rhizoma Smilacis Glabrae (a type of Chinese medicinal herb), has been reported to exert numerous bioactivities, including antioxidative and antibacterial activities. 34 The compound also demonstrates functionality for the treatment of autoimmune diseases. 35,36 Studies have reported that astilbin exerts pharmacological effects by blocking the NF-κB signalling pathway and alleviating MAPK signalling cascades.…”

Section: Discussionmentioning

confidence: 99%

Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis

Jin

Wang

Chen

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Osteoporosis is the most common osteolytic disease characterized by excessive osteoclast formation and resultant bone loss, which afflicts millions of patients around the world. Astilbin, a traditional herb, is known to have anti‐inflammatory, antioxidant and antihepatic properties, but its role in osteoporosis treatment has not yet been confirmed. In our study, astilbin was found to have an inhibitory effect on the RANKL‐induced formation and function of OCs in a dose‐dependent manner without cytotoxicity. These effects were attributed to its ability to suppress the activity of two transcription factors (NFATc1 and c‐Fos) indispensable for osteoclast formation, followed by inhibition of the expression of bone resorption‐related genes and proteins (Acp5/TRAcP, CTSK, V‐ATPase‐d2 and integrin β3). Furthermore, we examined the underlying mechanisms and found that astilbin repressed osteoclastogenesis by blocking Ca2+ oscillations and the NF‐κB and MAPK pathways. In addition, the therapeutic effect of MA on preventing bone loss in vivo was further confirmed in an ovariectomized mouse model. Therefore, considering its ability to inhibit RANKL‐mediated osteoclastogenesis and the underlying mechanisms, astilbin might be a potential candidate for treating osteolytic bone diseases.

show abstract

“…Astilbin has attracted considerable attention because of its anti‐inflammatory and anti‐oxidative properties . It can alleviate psoriasis‐like skin lesions by inhibiting Th17‐related inflammation and ameliorate cisplatin‐induced nephrotoxicity by reducing ROS accumulation . In addition, astilbin can promote angiotensin‐converting enzyme inhibition in vitro and protect diabetic rat heart against ischaemia‐reperfusion injury .…”

Section: Introductionmentioning

confidence: 99%

“…6,7 It can alleviate psoriasis-like skin lesions by inhibiting Th17-related inflammation 8 and ameliorate cisplatin-induced nephrotoxicity by reducing ROS accumulation. 9 In addition, astilbin can promote angiotensin-converting enzyme inhibition in vitro 10 and protect diabetic rat heart against ischaemia-reperfusion injury. 11 In a previous study, we reported that astilbin ameliorates fibrosis via blockade of the Hedgehog signalling pathway, in which we mainly focused on the role of coding RNAs under astilbin treatment.…”

mentioning

confidence: 99%

Regulatory network of two circRNAs and an miRNA with their targeted genes under astilbin treatment in pulmonary fibrosis

Zhang

Liu

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Circular RNAs (circRNAs) are becoming new therapeutic drug targets. However, their profiles under astilbin treatment have not been reported yet. In this study, we analysed the global reprogramming of circRNA transcriptome and a regulatory network of circRNAs with their targeted genes under astilbin treatment in pulmonary fibrosis. A total of 145 circRNAs were differentially expressed in the astilbin‐treated group compared with the bleomycin‐treated group using RNA sequencing. In the bleomycin‐ and astilbin‐treated groups, 29 coexpressed circRNAs were found. The maximum number of circRNAs was distributed on chromosome two, and their length varieties were mainly within 1000 bp. Four differentially expressed circRNAs (circRNA‐662, 949, 394 and 986) were tested to validate the RNA sequencing data, and their targeted microRNAs and genes were analysed by qRT‐PCR, Western blot, Pearson correlation coefficient, a dual‐luciferase reporter system and anti‐AGO2 RNA immunoprecipitation. The results showed that circRNA‐662 and 949 can act as “miR‐29b sponges” targeting Gli2 and STAT3 to exert their functions. Our work suggests that the transcriptome complexity at the circRNA level under astilbin treatment. These circRNAs may be potential molecular targets for drug action.

show abstract

Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing oxidative stress and inflammation

Cited by 96 publications

References 42 publications

Reversing ROS‐mediated neurotoxicity by chlorogenic acid involves its direct antioxidant activity and activation of Nrf2‐ARE signaling pathway

Reversing ROS‐mediated neurotoxicity by chlorogenic acid involves its direct antioxidant activity and activation of Nrf2‐ARE signaling pathway

Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis

Regulatory network of two circRNAs and an miRNA with their targeted genes under astilbin treatment in pulmonary fibrosis

Contact Info

Product

Resources

About